These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30910434)

  • 21. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S; McKay K; Vidmar S; O'Brien K; Stacey S; Cheney J; Wainwright CE
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements.
    Chuchalin A; Amelina E; Bianco F
    Pulm Pharmacol Ther; 2009 Dec; 22(6):526-32. PubMed ID: 19616111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
    Moss RB
    Chest; 2002 Jan; 121(1):55-63. PubMed ID: 11796432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation.
    Langley A; Cottingham L
    Am J Health Syst Pharm; 2011 Aug; 68(15):1385-6. PubMed ID: 21785021
    [No Abstract]   [Full Text] [Related]  

  • 30. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
    Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
    Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
    [No Abstract]   [Full Text] [Related]  

  • 31. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J; Schwarz C; Sommerwerck U; Nash EF; Tamm M; Cao W; Mastoridis P; Debonnett L; Hamed K
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.
    Ogier JM; Lockhart PJ; Burt RA
    Hear Res; 2020 Feb; 386():107870. PubMed ID: 31864009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
    Berlana D; Llop JM; Manresa F; Jódar R
    Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aminoglycoside Vestibulotoxicity.
    Rutka J
    Adv Otorhinolaryngol; 2019; 82():101-110. PubMed ID: 30947191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.
    Antoniu S
    Expert Rev Anti Infect Ther; 2015 Jul; 13(7):897-905. PubMed ID: 25921312
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
    Mordasini C; Aebischer CC; Schoch OD
    Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis.
    Smith AL; Ramsey BW; Hedges DL; Hack B; Williams-Warren J; Weber A; Gore EJ; Redding GJ
    Pediatr Pulmonol; 1989; 7(4):265-71. PubMed ID: 2515523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal toxicity due to inhaled tobramycin in lung transplant recipients.
    Laporta R; Ussetti P; Carreño MC
    J Heart Lung Transplant; 2006 May; 25(5):608. PubMed ID: 16678043
    [No Abstract]   [Full Text] [Related]  

  • 39. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
    Parkins MD; Elborn JS
    Expert Rev Respir Med; 2011 Oct; 5(5):609-22. PubMed ID: 21955231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas.
    Noah TL; Ivins SS; Abode KA; Stewart PW; Michelson PH; Harris WT; Henry MM; Leigh MW
    Pediatr Pulmonol; 2010 Mar; 45(3):281-90. PubMed ID: 20146365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.